leap:up GmbH (a partner of the German biotech association biosaxony) empowers founders, startups, and SMEs in the life sciences to take significant steps towards innovation, market entry, commercialization, and growth. Our vision: A sustainably healthier world. Our mission is to support scientists, companies and startups in the field of life sciences to transform their innovative ideas into scalable business models. Through our projects and world-class services, we help to bridge the gap between idea and realization. “leap:up” stands for bold leaps into the future of life sciences. As a life science enabler, we create optimal conditions for the realization of groundbreaking ideas. Our portfolio includes acceleration and development services for life science projects, regulatory support, training programs, and events through our in-house academy, as well as the provision of state-of-the-art co-working labs in Leipzig. We are actively expanding our international presence and service, including investor relations and funding opportunities. Our focus areas include diagnostics, cell and gene therapy, radiopharmacy, smart medical devices, robotics and AI, digital health, and phage therapy.
KyooBe Tech GmbH
KyooBe Tech focuses on the development and commercialization of innovative production technologies for biopharmaceuticals, combining state-of-the-art robotics, automation and biotechnological expertise to create sustainable and integrated process solutions. The key areas of activity involve pathogen inactivation and the automated production of personalized cell and gene therapies. KyooBe Tech has a strong affiliation with Bausch+Ströbel SE + Co. KG, a globally trusted partner for supply in Fill&Finish.
Kaneka Eurogentec
Founded in 1985 and part of Kaneka Corporation since 2010, Eurogentec is a leading biotechnology and CDMO company specializing in GMP-certified manufacturing of starting materials and APIs. With facilities in Europe and the USA, we support plasmid DNA, mRNA, recombinant proteins, peptides, antibody fragments, and therapeutic oligonucleotides from early research to clinical and commercial production. Our expertise in process development and scale-up ensures high-quality solutions at every stage. Detailed Description of Products (Event Specific) max 500 characters in English – Plasmid DNA – Starting material & APIs including Nano-plasmids & Minicircle DNA. FastTrack: 4-month production. – mRNA – IVT mRNA (0.1g–50g), saRNA, gRNA with co-/post-transcriptional modifications. – Proteins – GMP production in E. coli & P. pastoris for biotech & pharma. – Conjugates – Chemically modified recombinant proteins for clinical use. – Therapeutic Oligos – ASOs, siRNA, aptamers, CpG oligos. – Peptides – Linear, cyclic & complex-modified. – Antibody Fragments – scFv, Fab, VHH, bispecifics.
JRF Global
JRF Global is a Premier preclinical GLP CRO dedicated to advancing innovative therapies from discovery to regulatory approval. With a strong commitment to scientific excellence and regulatory compliance, JRF Global delivers high-quality research solutions that support successful submissions to leading health authorities, including the U.S. Food and Drug Administration and the European Medicines Agency. Backed by experienced scientists, state-of-the-art facilities, and rigorous Good Laboratory Practice (GLP) standards, JRF Global provides comprehensive preclinical services—from toxicology and safety pharmacology to pharmacokinetics, bioanalysis, and pathology. Each study is designed to generate reliable, regulatory-ready data that accelerates the development of pharmaceuticals, biotechnology products, and medical devices. By combining scientific expertise with a client-focused approach, JRF Global empowers global innovators to move their discoveries forward with confidence—transforming promising ideas into life-changing medical solutions. | JRF Global is a leading Preclinical Contract Research Organization (CRO) offering comprehensive Preclinical IND-enabling Studies (GLP and non-GLP) to the pharmaceutical and biotechnology industries. With decades of scientific expertise and 28+ years of GLP-compliant, we support Drug Development across the entire lifecycle—from Discovery through to regulatory submission (IND/NDA). Our tailored solutions in Toxicology, environmental risk assessment, and Analytical chemistry and Bioanalytical help clients meet global regulatory standards with precision and efficiency.
Iris Biotech GmbH
Iris Biotech is providing high quality products for the fields peptide synthesis, linkerology, drug delivery, and life sciences in flexible quantities from research scale to commercial production, for academia as well as industry. Besides our broad portfolio from standard to exotic, we have the know-how and facilities to manufacture your compound of choice based on a Custom Synthesis. All our services are rounded off by a strong and competent personnel customer support. We are in continuous exchange with scientists all around the world to gather ideas and be ahead regarding technologies and innovations true to our slogan Empowering Peptide Innovation. | Founded in 2001, Iris Biotech provides scientists in both industry and academia with innovative and rare compounds, while also being your reliable partner for a comprehensive supply of standard consumables. Guided by our dedication to deliver competent service as well as the highest quality to our customers, our company’s focus remains Peptide Chemistry, while we also have strong expertise in Drug Delivery, Life Sciences, and Linkerology. Due to the growing demand for tailor-made compounds and solutions, we further increased our Custom Synthesis capabilities in 2013. Our skilled scientists and technicians offer profound expertise in the custom manufacturing of both simple and complex molecules. | Empowering Peptide Innovation With this guiding theme in mind, Iris Biotech’s mission is to support researchers by supplying • innovative technologies, • rare compounds, • as well as a broad portfolio on standard consumables, available in flexible quantities from small scale to bulk quantities. Guided by our dedication to provide • competent service, • as well as novel substances and • latest technologies, Iris Biotech is your trusted partner for the world of peptides, while having strong expertise in associated disciplines. Thus, our portfolio comprises reagents and tools for the synthesis and modification of peptides, e.g., amino acids, resins and solvents but also for related technologies such as drug delivery, linkerology® and life sciences. Your project requires a compound not listed in our portfolio? Get in contact and inquire about our custom synthesis capabilities. | Empowering Peptide Innovation – this is our guiding principle. Iris Biotech stands for innovation and know-how in the field of pharmaceuticals and biotechnology. With this guiding theme in mind, Iris Biotech attends various conferences, symposia and exhibitions each year, which allows us to remain in direct contact with scientists from academia and industry alike, in order to exchange knowledge, and to gather new ideas to tackle your current challenges. Our mission as qualified supplier and competent consultant is to support our customers in their ongoing projects from research scale to commercial production.
iPark Institute Co., Ltd.
Shonan Health Innovation Park (Shonan iPark) is Japan’s firstpharmaceutical-initiated science park, established in April 2018 when Takeda Pharmaceutical Company Limited (Takeda) opened its then in-house research center to outside organizations. It aims to become a place where industry, government, and academia from a wide range of industries and sizes can come together to accelerate health innovation. Shonan iPark is currently home to about 190 companies and more than 2,500 people (as of February, 2025) from not only pharmaceutical companies but also next-generation medicine, cell agriculture, AI, government, and other fields, forming an ecosystem.
Invitris GmbH
Invitris co-develops highly complex multi-proteins using a scalable in vitro protein synthesis platform. Invitris provides both drug discovery & development, and can also provide GMP manufacturing without extensive process development. Invitris product portfolio includes synthetic bacteriophages, endolysins, tailocins, neoantigens, antibodies, ADCs, proteases, nucleases, enzymes, and many more. | We own a cell-free in vitro expression technology platform, PhactoryTM, to help co-develop & manufacture the next generation of proteins. We are capable of both prokaryotic and Mammalian cell-free expression. Our focus areas are microbial and Mammalian proteins, including bacteriophages, viruses, endolysins, tailocins, enzymes, antibodies, nanobodies, and more. We’re active in the fields of oncology, neurogenerative diseases, antibiotics, agriculture, technical industries, and more. | x
Inventage Lab Inc
.. | Inventage Lab(KOSDAQ: 389470) is a clinical-stage biopharmaceutical company specializing in drug delivery system, especially the development of long-acting injectables and lipid nanoparticles using a microfluidic manufacturing platform. IVL-DrugFluidic® platform enables the production of high-quality of microsphere based long-acting injectable formulations by eliminating initial drug over-release and ensuring the mass production of uniform microspheres. It has been successfully applied to veterinary medicine and clinical trials for androgenic alopecia, dementia, and addiction treatments. The platform also supports drug re-discovery and partnerships for novel drug formulations with partnering pharmaceutical companies. Harnessing our HANDYGENE™ system, this platform focuses on developing lipid nanoparticles (LNPs) for vaccines and gene therapies. Inventage Lab also offers services, including LNP formulation and non-clinical and clinical sample production, while diversifying its business through selling and subscribing to its LNP manufacturing equipment.
INTRAVACC
Intravacc is an established independent CDMO with years of experience in developing and optimizing vaccines for infectious diseases and therapeutic vaccines, which has transferred its technology worldwide for vaccines against polio, measles, diphtheria, Hib, and influenza. Around 30% of childhood disease vaccines are based on Intravacc’s technology and knowhow. Intravacc offers a wide range of expertise for independent vaccine development, from concept to Phase I/II clinical studies, for customers around the world. Intravacc continues to capitalize on the critical global trends in healthcare: the ever-growing need for prevention and intervention for infectious diseases and cancer. Our innovative vaccine platforms and vaccine contract development and manufacturing capabilities are well positioned to address the unmet needs in the vaccine and immune therapy market which is currently estimated at $37 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 6.6% to $55 billion by 2027. The company’s head office is located on the Utrecht Science Park location Bilthoven, The Netherlands, and has state-of-the-art laboratories and GMP production facilities. Intravacc B.V. is a limited liability company incorporated under Dutch law. Intravacc is a state holding company since 1 January 2021, under the Ministry of Health, Welfare and Sports (VWS). | . | Your specialized CDMO to accelerate the development of your viral, bacterial, therapeutic, and conjugate vaccines. From discovery to phase II clinical trial. Based in the Netherlands within the Utrecht Science Park in Bilthoven, Intravacc is a globally recognized pioneer and leader in translational vaccinology. With decades of experience, we stand as an independent Contract Development and Manufacturing Organization (CDMO) within the vaccine industry. Our purpose is to serve as the vital link between your discoveries and early-stage clinical trials of new vaccines. We understand that this journey from concept to GMP production is often riddled with challenges, and we specialize in mitigating risks and reducing costs. | Your specialized CDMO for viral, bacterial, therapeutic, and conjugate vaccines Based in the Netherlands and nestled within the Utrecht Science Park in Bilthoven, Intravacc is a globally recognized leader in translational vaccinology. With decades of experience, we stand as an independent Contract Development and Manufacturing Organization (CDMO) within the vaccine industry. Our purpose is to serve as the vital link between your discoveries and early-stage clinical trials. We understand that this journey from concept to GMP production is often riddled with challenges, and we specialize in mitigating risks and reducing costs. The entire team at Intravacc is committed to blazing new paths in vaccine development. We have an exceptional track record imagining and realizing technologies that enable tomorrow’s vaccines. That expertise in vaccine development is at the core of our CDMO services and candidate vaccines out-licensing.
Indian Immunologicals Ltd
Indian Immunologicals Limited (IIL) is a leading vaccine manufacturer. We are a fully integrated player, conceptualizing and executing the products journey from bench at the R&D lab to its sale at the clinic. Our journey of forty years of saving lives through developing, scaling up and executing huge scale manufacturing projects has honed our skills of projects management, efficient execution, excellence in regulatory compliance and at the same time offering agility, competitiveness, and trusted result-oriented approach. IIL has a strong portfolio of products, both in the human health segment and animal health segment. We have been spearheading the One Health initiative, globally. As a result of our presence in these two segments, we recognized both, the inter-dependence, and inter-linkages of the two segments and as a result have been spearheading the One Health initiative since a long time. IIL had its humble beginnings as a veterinary vaccine manufacturing company in the year 1982. Since then, it has scaled up to become one of the major vaccines manufacturer of the country and the region. We ventured into manufacturing human vaccines by 1998 on specific request by the Government of India. As a result, IIL became the second company in the world and first in India to launch purified vero cell rabies vaccine (PVRV) and markets it under the brand – Abhayrab. It is today by far the largest manufacturer of human rabies vaccine in the world. IIL today has a portfolio of eight commercial human vaccines and has a pipeline of nine new vaccine candidates. We have a huge pipeline of vaccine for Animal Health segment. We are one of the leading manufacturers of Pet Vaccines. IIL has four world class manufacturing facilities spread across India and New Zealand. IIL collaborates with several leading pharma/vaccines companies within India and outside for manufacturing and research collaborations. Our capabilities and experience in handling projects across varied platforms technologies, across varied scales (small to very high) enable us to offer both flexibility and confidence to our partners for a smooth execution. We solicit cooperation proposals to build synergistic relationships. | Indian Immunologicals Limited (IIL) is a leading vaccine manufacturer. We are a fully integrated player that conceptualizes and executes the products journey from bench at the R&D lab to its use at the clinic. Our journey of forty years of saving lives through developing, scaling up and executing huge scale manufacturing projects has honed our skills of projects management, efficient execution, excellence in regulatory compliance and at the same time offering agility, competitiveness, and trusted result-oriented approach. IIL has a strong portfolio of products, both in the human health segment and animal health segment. We have been spearheading the One Health initiative, globally. As a result of our presence in the two segments, we recognized both, the interdependence, and interlinkages of the two segments and as a result have been spearheading the One Health initiative for a long time. IIL has its humble beginnings as a veterinary vaccine manufacturing company in the year 1982. Since then, it has scaled up to become one of the major vaccines manufacturers of the region. After starting off an animal vaccine manufacturer, we started manufacturing human vaccines in 1998 on a specific request by the Government of India. As a result, IIL became the second company in the world and first in India to launch purified vero cell rabies vaccine (PVRV) and markets it under the brand – Abhayrab. It is today by far the largest manufacturer of human rabies vaccine in the world. IIL today has a portfolio of eight commercial human vaccines and has a pipeline of five new vaccine candidates. We are currently serving and touching lives in more than fifty (60) countries by exporting both our animal health and human health products. We have four world class manufacturing units spear across India and New Zealand. IIL, through its state-of-the-art facilities, collaborates with several leading pharma/vaccines companies within India and outside.